CALGARY, AB — November 24, 2025 — Leads & Copy — Nanalysis Scientific Corp. (TSXV: NSCI, OTCQX: NSCIF, FRA: 1N1), a leader in portable NMR spectrometers and MRI technology, has announced its third-quarter results for the period ending September 30, 2025.
The company reported consolidated revenue of $9,285 for the three months ended September 30, 2025, a 12% decrease compared to the $10,570 reported in the same period in 2024. The decline is attributed to a reduction in third-party equipment sales contracts and overall macro-economic uncertainty due to tariffs and trade disputes globally. Sales of capital equipment remained slow during the quarter.
Revenue within the Security Services segment increased by 10% year-over-year due to increased project work related to the Airport Security Maintenance Business.
Gross margin percentage for product sales was 44% for the three months ended September 30, 2025, compared to 52% in the same period in 2024. Supply chain challenges that slowed manufacturing activity negatively impacted gross margins for the quarter, which were resolved in mid-Q4 2025. Gross margins for the nine-month period ended September 30, 2025, increased by 8% over the same period in the prior year due to continuous improvement programs within manufacturing.
Gross margin percentage for security services was consistent with the prior year at 14%, compared to 15% in the same period in 2024. Improvements in scheduling, logistics processes, and overtime management have steadily improved margins from their Q1 2025 low point of 6%.
Adjusted EBITDA loss for the three months ended September 30, 2025, was ($2), compared to Adjusted EBITDA of $545 in the same period in 2024. This decrease was primarily due to a drop in scientific equipment sales.
Net loss was $1,500 for the three months ended September 30, 2025, an improvement of $144 from the comparative period in 2024. The decrease in net loss was due to lower depreciation as an acquired, depreciable, intangible asset was fully impaired in 2024, and losses from associate are no longer recorded in the consolidated statement of loss and comprehensive loss due to the impairment of the Quad investment in 2024.
For the nine months ended September 30, 2025, Nanalysis reported consolidated revenue of $29,455, an 11% decrease compared to the $33,206 reported in the same period in 2024. The decrease was primarily due to a $4,552 decrease in product sales, offset by an $801 increase in security services revenue.
Gross margin percentage on product sales was 58% for the nine months ended September 30, 2025, up from 50% in the prior year. Gross margin percentage on service revenue was 10%, compared to 11% in 2024.
Adjusted EBITDA loss for the nine months ended September 30, 2025, was ($284) versus Adjusted EBITDA of $1,200 for the same period last year. The decrease was primarily due to the drop in product sales, offset by improved gross margins on both product and service revenues.
Recent strategic and operational highlights include:
- Strategic OEM partnership with IMRIS for intra-operative MRI systems.
- Execution of a multi-year cost-reduction and continuous improvement program.
- Resolution of magnet supply constraints.
- Announcement of the first regulated benchtop NMR assay for pharmaceutical quality control.
- Integration with Wiley’s KnowItAll software and spectral libraries.
Sean Krakiwsky, Founder and CEO of Nanalysis, said that the company is restructuring its direct sales and distributor management organizations and will provide shareholders with regular updates on the performance of the revitalized product revenue organization.
Sean Krakiwsky and Randall McRae will host a conference call at 4:15 P.M. Eastern Time today to discuss the results. Investors can join the live call through Zoom using the details provided in the press release.
Sean Krakiwsky, Founder and CEO of Nanalysis. Randall McRae, Chief Financial Officer.
Contact:
Sean Krakiwsky
Chief Executive Officer
Source: Nanalysis Scientific Corp.
